Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPI-47
- Development stage
- Unknown
- Lead developer
- Sparrow Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**SPI-47** is Sparrow Pharmaceuticals' investigational fixed-dose oral combination of **clofutriben** and **prednisolone** being developed for polymyalgia rheumatica. Clofutriben is a potent, selective inhibitor of corticosteroid 11-beta-dehydrogenase isozyme 1, an intracellular enzyme that regenerates active cortisol from cortisone in tissues associated with glucocorticoid toxicity. Prednisolone is a glucocorticoid receptor agonist that suppresses inflammation. The combination is intended to preserve prednisolone's anti-inflammatory benefit while reducing tissue glucocorticoid exposure and steroid-related toxicity. ([sparrowpharma.com](https://sparrowpharma.com/news/sparrowacr2024-r5283-p222h-f5j9r-xr7k9-9bxdk-wlsps))
- Other names
- clofutriben + prednisoloneSPI-62 + prednisoloneSPI-62/prednisolone
02
Targets
HSD11B1 (11-beta-hydroxysteroid dehydrogenase type 1)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on SPI-47.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPI-47.